Holen Sie sich die Stockscreener-App
2.06
1.48%
0.03
Vorhandelsmarkt:
2.08
0.02
+0.97%
Schlusskurs vom Vortag:
$2.03
Offen:
$2.12
24-Stunden-Volumen:
4.39M
Relative Volume:
1.06
Marktkapitalisierung:
$653.68M
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-3.9615
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
-5.94%
1M Leistung:
-14.17%
6M Leistung:
-30.41%
1J Leistung:
-46.21%
1-Tages-Spanne:
$2.04
$2.1492
1-Wochen-Bereich:
$1.98
$2.1892
52-Wochen-Spanne:
$1.8906
$4.3398
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.06 | 653.68M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera (ABCL) Wins Patent Validation Case in Federal Circuit - GuruFocus
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by t - GuruFocus
AbCellera patent upheld in Federal Circuit Court ruling - Investing.com
Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit - marketscreener.com
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus
Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus
AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - MSN
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Investments - GuruFocus
AbCellera Biologics Reports Q1 2025 Financial Results - TipRanks
AbCellera (ABCL) Advances Clinical Programs with Strong Financial Position - GuruFocus
Abcellera Biologics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
AbCellera Reports Q1 2025 Business Results - BioSpace
AbCellera (ABCL) Misses Revenue Projections, Advances New Antibody Treatment | ABCL Stock News - GuruFocus
AbCellera Biologics Inc Reports Q1 2025 Earnings: EPS of $(0.15) Misses Estimate, Revenue Falls Short at $4.2 Million - GuruFocus
2 Reasons to Watch EAT and 1 to Stay Cautious - The Globe and Mail
AbCellera Biologics (ABCL) Q1 Earnings Preview: Analysts Expect Lower Revenue - GuruFocus
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Abcellera at Bloom Burton: Strategic Shift in Biotech Development By Investing.com - Investing.com UK
Kiwetinohk announces upcoming first quarter 2025 earnings release - The Globe and Mail
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - BioSpace
AbCellera (ABCL) Unveils Promising Preclinical Results for T-Cel - GuruFocus
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x C - GuruFocus
AbCellera reports promising preclinical TCE cancer therapy data - Investing.com
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 | ABCL Stock News - GuruFocus
Equinox Gold: Scaling Up to the Million-Ounce Club - The Globe and Mail
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
Dow Jones Index Today: Nvidia Leads a Tech Stock Drop - The Globe and Mail
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
What to Expect in the Week Ahead: Inflation Data, Bank Earnings, and More Tariff Concerns - The Globe and Mail
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
Netflix Poised for Significant Rally as a Safe Haven Stock - The Globe and Mail
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):